PRESS RELEASES

Parcom Capital acquires Viroclinics Biosciences

Parcom Capital has acquired the successful clinical research organisation Viroclinics Biosciences. Viroclinics believes Parcom is the perfect partner to help it realise its growth ambitions.

Viroclinics Biosciences endorsed for GLP compliancy

Viroclinics Biosciences serves as a virology contract research organization in the bio pharmaceutical community with preclinical, clinical diagnostic, assay development and clinical trial logistics services. Especially with extensive experience in clinical and...

↓